XML 79 R62.htm IDEA: XBRL DOCUMENT v3.20.4
Collaboration, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended 20 Months Ended
Dec. 31, 2020
Sep. 30, 2019
May 31, 2018
Sep. 30, 2020
Jun. 30, 2019
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2018
Nov. 30, 2020
Oct. 16, 2018
Sep. 30, 2018
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services           $ 65,144,000 $ 63,038,000        
Deferred revenue $ 34,937,000         34,937,000 40,847,000 $ 47,565,000      
Deferred revenue - current 33,275,000         33,275,000 32,503,000        
Deferred revenue - long term 1,662,000         1,662,000 8,344,000        
Collaborations and services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services           32,820,000 37,734,000        
Commercial product sales                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services           32,324,000 25,304,000        
Collaboration and License Agreement | United Therapeutics Corporation                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received                   $ 45,000,000.0  
Milestone Payment Received                 $ 12,500,000    
Total transaction price 105,800,000         105,800,000          
Increase in total consideration 2,700,000                    
Deferred revenue 33,100,000         33,100,000          
Collaboration and License Agreement | United Therapeutics Corporation | Clinical Supplies                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue - current 1,200,000         1,200,000          
Collaboration and License Agreement | United Therapeutics Corporation | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Additional option exercise and development milestone payments to be receive 40,000,000.0         40,000,000.0          
Collaboration and License Agreement | United Therapeutics Corporation | Collaborations and services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services       $ 400,000              
Research Agreement | United Therapeutics Corporation                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Upfront payment received                     $ 10,000,000.0
Total transaction price 10,000,000.0         10,000,000.0          
Research Agreement | United Therapeutics Corporation | Maximum                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Potential milestone payments to be receive 30,000,000.0         30,000,000.0          
Research Agreement | United Therapeutics Corporation | Collaborations and services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services           210,000 6,032,000        
Research Agreement | United Therapeutics Corporation | Engineering Consulting Services                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total transaction price 1,000,000.0         $ 1,000,000.0          
Revenue performance obligation, method used           The revenue for the engineering consulting services was recognized using a ratable method until the obligation was satisfied. The Company believed that this method best reflected the measure of progress toward complete satisfaction of the performance obligation.          
Research Agreement | United Therapeutics Corporation | Product Prototype                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Total transaction price 9,000,000.0         $ 9,000,000.0          
Revenue performance obligation, method used           The revenue for the product prototype was recognized using an output method (based on project milestones achieved and surveys of performance completed to date). The Company believed that this method best reflected the measure of progress toward complete satisfaction of the performance obligation.          
Supply and Distribution Agreement | Commercial product sales | Biomm                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services   $ 700,000     $ 200,000 $ 0          
License and Distribution Agreement | Foreign Country | India Tax Authority                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Income Taxes Paid               $ 200,000      
License and Distribution Agreement | Cipla Ltd                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Deferred revenue 1,800,000         1,800,000          
Deferred revenue - current 100,000         100,000          
Marketing and distribution agreement date     2018-05                
Deferred revenue - long term $ 1,700,000         1,700,000          
License and Distribution Agreement | Collaborations and services | Cipla Ltd                      
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                      
Revenue' collaborations and services           $ 147,000 $ 148,000